

Need For Continuing Cost-Effectiveness and Cost Utility Studies in Diabetes Care

Editor:

A recent issue of *Diabetes Spectrum* included a special section on economic issues in diabetes care and management. Included in the collection was the abstract of an often-cited paper by Elixhauser.¹ The Elixhauser paper notes deficiencies in studies evaluating the cost-effectiveness of care to prevent complications of diabetes mellitus. Although supportive of diabetes education and counseling, Elixhauser expressed concern that methodological weaknesses in studies that have been reported in the literature may lead to challenges by economically sophisticated policy analysts. Her conclusions were similar to a review we had conducted a few years earlier.²

Accompanying the abstract was a commentary by Jan Norman³ suggesting that, "...a definitive study to prove that

diabetes education improves health outcome is not necessary or affordable at this time." (p. 158). Norman's commentary reflects the frustration many providers feel with the managed health care movement. However, her conclusions may lead to abandonment rather than support for diabetes education and counseling.

Health-care costs remain out of control and it is almost certain that federal and private attempts to manage costs will continue. Diabetes experts are among many providers competing for the same resources. Health-care administrators need to use data in order to determine the best use of their limited resources.⁴ A movement toward the development of empirically-based practice guidelines is beginning to take hold.⁵ Without empirical data from well-designed studies, assertions that particular treatments are cost-effectiveness will not be credible.

Norman suggested that the effectiveness of diabetes education has already been proven in the Diabetes Control and Complications Trial (DCCT). However, the principle variable manipulated in the DCCT was not patient education. Rather, it was tight metabolic control. Certainly

patient education and counseling contributed to this effective treatment, but the exciting DCCT findings cannot be attributed exclusively to health educators, and the DCCT data do not allow an estimate of the unique portion of the benefit attributable to educational services.

Virtually all areas of medicine and health care have been faced with the challenge of producing impartial outcomes data. Norman argues, "In this economic climate of scarce research dollars, one would have to question the judgment of using this limited resource to prove that diabetes education affects the clinical and economic impact of diabetes. This fact was already proved in the DCCT. Further research in this area could come at the expense of dollars invested to find a cure for diabetes." (p. 159) Outcomes research represents a very small piece of the total investment in diabetes investigation. However, the results of outcome studies are enormously important for selecting the care that will be given to virtually all patients with this illness.

All of us are frustrated by the economic realities of contemporary health care. However, the challenge is to prove the value of diabetes care using the best

EDITOR

Elizabeth A. Walker, DNSc, RN, CDE

ASSOCIATE EDITORS

Martha M. Funnell, MS, RN, CDE
Debra Haire-Joshu, PhD, RN
Timothy J. Ives, PharmD, MPH, CDE
Annette M. La Greca, PhD
Robert E. Ratner, MD, FACP, CDE
Lesley Fels Tinker, PhD, RD

EDITORIAL BOARD

Lynda A. Anderson, PhD
Lois Babione, MS, RD, CDE
Ellen D. Davis, MS, RN, CDE
Linda M. Delahanty, MS, RD
Samuel Engel, MD
Scott Jacober, DO, CDE
Donna Jornsay, BSN, RN, CPNP, CDE
Gayle Lorenzi, RN, CDE
Arshag D. Mooradian, MD
Lee J. Sanders, DPM
Dawn Satterfield, MSN, RN, CDE
Kim Starrett-Monroe, MA, RD, CDE
Tim Wysocki, PhD

ADVERTISING REPRESENTATIVES

Diabetes-related pharmaceutical accounts
Pharmaceutical Media, Inc., 30 East 33rd Street, New York, NY 10016 (212) 685-5010 Kathleen McGorty

Other Accounts

Northeast

The Coppola Group, 392 Central Park West, Suite 7U, New York, NY 10025 (212) 678-4652 Fax: (212) 316-7641

Midwest

Fox Associates, Inc., 116 West Kinzie Street, Chicago, IL 60610 (312) 644-3888 Fax: (312) 644-8718

West

Bill Cooper & Associates, 1000 Elwell Court, Suite 234, Palo Alto, CA 94303 (415) 965-4334

Other Regions

American Diabetes Association, 1660 Duke Street, Alexandria, VA 22314 (703) 549-1500 Fax: (703) 683-2890

PUBLISHER

Susan H. Lau

EDITORIAL DIRECTOR

Peter Banks

MANAGING EDITOR

Debbie Fentress

ASSISTANT MANAGING EDITOR

Laurie Guffey

PRODUCTION EDITOR

Stacey N. Wages

DIRECTOR OF MEMBERSHIP/SUBSCRIPTION SERVICES

Bill Outlaw

CUSTOMER SERVICE MANAGER

Stephen Laseau

DIRECTOR OF ADVERTISING AND MARKETING

Len Boswell

ADVERTISING MANAGER

Carol Ann Flynn

OUR MISSION

The mission of the American Diabetes Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

American Diabetes Association Officers 1995-1996

CHAIR OF THE BOARD

David H. McClure

PRESIDENT

Frank Vinicor, MD, MPH

SENIOR VICE PRESIDENT

David F. Kruger, MSN, RN, C, CDE

CHAIR OF THE BOARD-ELECT

Alan Altschuler

PRESIDENT-ELECT

Philip E. Cryer, MD

SENIOR VICE PRESIDENT-ELECT

Belinda P. Childs, MN, RN, CDE

VICE CHAIR OF THE BOARD

Stephen J. Satalino

VICE PRESIDENT

Christine Beebe, RD, MS, CDE

SECRETARY

Denise E. Dodero

TREASURER

Roger K. Towle

CHIEF EXECUTIVE OFFICER

John H. Graham IV

scientific data. Until a cure for diabetes is found, we must continue to focus on methods for most effectively and efficiently using our resources to improve patient outcomes. That interest will best be served by new systematic and impartial outcome studies that use randomized designs, quality of life outcome measures, and thorough cost accounting. ■

Robert M. Kaplan, PhD
 Department of Family and
 Preventive Medicine
 University of California, San Diego

• REFERENCES •

¹Elixhauser, A: The cost-effectiveness of preventive care of diabetes mellitus. *Diabetes Spectrum* 2:349-53, 1989.

²Kaplan RM, Davis WK: Evaluating the costs and benefits of out-patient diabetes education and nutrition counseling. *Diabetes Care* 9:81-86, 1986.

³Norman J: Summary and Commentary. *Diabetes Spectrum* 8:158-59, 1995.

⁴Kaplan RM: *The Hippocratic predicament: affordability, access, and accountability in American health care*. San Diego, Calif., Academic Press, 1993.

⁵Eddy DM: Rationing resources while improving quality: how to get more for less. *JAMA* 272:817-24, 1994.

Feel free to recommend it.

Safe Tussin™ 30 is a strong cough medication formulated without ingredients commonly restricted to patients with Diabetes, high blood pressure, Thyroid problems, heart disease and allergies. You see, Safe Tussin™ 30 contains no sugar, no alcohol, no antihistamines and no artificial colors or dyes. What it does contain is 30mg per dose of the potent cough suppressant Dextromethorphan, plus 200mg per dose of Guaifenesin for expectorant action. That makes Safe Tussin™ 30 stronger than most other cough medications now available. For stubborn coughs, recommend Safe Tussin™ 30 today!



SPECIAL OFFER

EDUCATIONAL VIDEO "UNDERSTANDING DIABETES"

This 30 minute educational video covers important topics and offers answers to questions most frequently asked by newly diagnosed diabetics and their families. The video educates you on how to better your life while keeping control of diabetes.

To order your educational video today please mail a check or money order for *19.95 to:
 Kramer Laboratories Inc., 8778 S.W. 8th St. Miami, FL 33174

NAME _____
 ADDRESS _____
 CITY _____ STATE _____ ZIP _____
 DAYTIME PHONE NUMBER _____



*Postage & Handling Included